At the clinical level, PCa patients with high GR-positivity showed a poor response to ENZ therapy (9), and increased GR levels were correlated with persistent tumors after androgen synthesis blocker abiraterone treatment (20). The gene discussed is NR3C1; the disease is posterior cortical atrophy.